Johan Rockberg

Johan Rockberg is a Professor at KTH Royal Institute of Technology, specializing in antibody technology and targeted evolution. His research focuses on optimizing the production of synthetic viruses for gene therapy, particularly addressing challenges such as cost reduction and efficiency enhancement in recombinant adeno-associated virus (AAV) generation. He employs advanced techniques like omics methods, CRISPR-Cas9 gene editing, and protein engineering to study cellular responses during viral production and improve therapeutic delivery systems.

His work integrates systems biology and bioprocessing to understand cellular demands for protein secretion and engineer cells for better performance. Recent studies emphasize modular platforms for targeted DNA delivery, automation in AAV production, and precision immunotherapy via bispecific antibodies and ADAC™ technology. These efforts aim to develop affordable treatments for conditions like blindness and paralysis, leveraging genetic improvements and molecular engineering.

In 2025, his research highlighted advancements in AAV production kinetics and T-cell response optimization. In 2024, contributions included bispecific CD40 antibodies for cancer therapy and novel cell display systems for epitope mapping. His 2023 studies further explored CHO cell engineering and stroma-targeted immune activation. No scientific awards or formal grants are explicitly mentioned in the provided texts.

While no specific lab or team affiliations are detailed, his work is collaborative, involving interdisciplinary approaches across virology, immunology, and biotechnology. His research narrative emphasizes bridging fundamental biology with translational applications to address critical bottlenecks in biologics production and delivery.